Using a novel selective α7 nAChR partial agonist S 24795, Wang et al. [96] showed that, in contrast to anti-AD drugs, galantamine (a cholinesterase inhibitor) and memantine (an N-methyl-D-aspartate (NMDA) receptor antagonist), S 24795 reduced or limited Aβ42-α7 nAChR association, Aβ42-induced tau phosphorylation, Aβ42 accumulations, and Aβ42-mediated inhibition of α7 nAChR Ca2+ influx in rodent brain [96]. Here, MAPT is linked to Alzheimer disease.